CN101687805A - 可用作血管加压素拮抗剂的苯并氮杂衍生物 - Google Patents

可用作血管加压素拮抗剂的苯并氮杂衍生物 Download PDF

Info

Publication number
CN101687805A
CN101687805A CN200880022253A CN200880022253A CN101687805A CN 101687805 A CN101687805 A CN 101687805A CN 200880022253 A CN200880022253 A CN 200880022253A CN 200880022253 A CN200880022253 A CN 200880022253A CN 101687805 A CN101687805 A CN 101687805A
Authority
CN
China
Prior art keywords
glycyl
methyl
group
compound
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880022253A
Other languages
English (en)
Chinese (zh)
Inventor
近藤一见
校条康宏
友安崇浩
宫村伸
友平裕三
松田贵邦
山田圭吾
加藤雄介
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of CN101687805A publication Critical patent/CN101687805A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200880022253A 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂衍生物 Pending CN101687805A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP167207/2007 2007-06-26
JP2007167207 2007-06-26
PCT/JP2008/062033 WO2009001968A1 (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN2013101949565A Division CN103342680A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物
CN2013101948844A Division CN103342679A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物

Publications (1)

Publication Number Publication Date
CN101687805A true CN101687805A (zh) 2010-03-31

Family

ID=39773045

Family Applications (3)

Application Number Title Priority Date Filing Date
CN200880022253A Pending CN101687805A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂衍生物
CN2013101949565A Pending CN103342680A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物
CN2013101948844A Pending CN103342679A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2013101949565A Pending CN103342680A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物
CN2013101948844A Pending CN103342679A (zh) 2007-06-26 2008-06-26 可用作血管加压素拮抗剂的苯并氮杂*衍生物

Country Status (27)

Country Link
US (3) US8669229B2 (enExample)
EP (3) EP2374798B1 (enExample)
JP (3) JP5653043B2 (enExample)
KR (1) KR101487201B1 (enExample)
CN (3) CN101687805A (enExample)
AR (1) AR067176A1 (enExample)
AT (1) ATE545633T1 (enExample)
AU (1) AU2008269918B2 (enExample)
BR (1) BRPI0813768A2 (enExample)
CA (1) CA2690335A1 (enExample)
CO (1) CO6160295A2 (enExample)
CY (3) CY1113519T1 (enExample)
DK (3) DK2374798T3 (enExample)
ES (3) ES2380085T3 (enExample)
HR (3) HRP20120310T1 (enExample)
IL (1) IL202561A0 (enExample)
MY (3) MY148312A (enExample)
NZ (3) NZ598064A (enExample)
PH (2) PH12012501363A1 (enExample)
PL (3) PL2374798T3 (enExample)
PT (3) PT2374797E (enExample)
RU (1) RU2471784C2 (enExample)
SG (2) SG182230A1 (enExample)
SI (3) SI2374797T1 (enExample)
TW (1) TWI459947B (enExample)
UA (1) UA98966C2 (enExample)
WO (1) WO2009001968A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260213A (zh) * 2011-05-31 2011-11-30 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
CN104902874A (zh) * 2012-12-28 2015-09-09 大塚制药株式会社 包含光学活性托伐普坦的可注射储库制剂及制造该制剂的方法
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
CN110891939A (zh) * 2017-06-30 2020-03-17 大塚制药株式会社 苯并氮杂卓衍生物
CN112851583A (zh) * 2021-01-19 2021-05-28 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
JP5656399B2 (ja) * 2008-12-26 2015-01-21 大塚製薬株式会社 医薬及び医薬製剤
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
JP5717645B2 (ja) * 2009-10-26 2015-05-13 大塚製薬株式会社 ベンズアゼピン化合物
GB201105537D0 (en) 2011-03-31 2011-05-18 Vantia Ltd New process
TWI704919B (zh) 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
KR20230143165A (ko) * 2021-02-10 2023-10-11 상하이 센후이 메디슨 컴퍼니 리미티드 벤즈아제핀 화합물, 이의 제조 방법 및 이의 약학적 용도
CN113112528A (zh) * 2021-04-26 2021-07-13 中南财经政法大学 异常行为监控方法、装置、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045478A (en) * 1986-03-03 1991-09-03 Becton Dickinson And Company Vesicles and use thereof in an assay
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
EP0602209A1 (en) 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
TW270927B (enExample) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
GB9726695D0 (en) 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
EA004436B1 (ru) * 1998-09-29 2004-04-29 Уайт Холдингз Корпорейшн Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
DE60102815D1 (de) 2000-05-15 2004-05-19 Paratek Pharm Innc 7-substituierte kondensierte ring-tetrazyclin- verbindungen
BRPI0516922A (pt) * 2004-11-02 2008-09-23 New River Pharmaceuticals Inc composto de ribavirina, método para fazer um composto de ribavirina, método para usar um composto de ribavirina e composição farmacêutica
CA2633929A1 (en) * 2005-12-27 2007-07-05 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102260213A (zh) * 2011-05-31 2011-11-30 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
CN102260213B (zh) * 2011-05-31 2013-05-15 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
CN104902874A (zh) * 2012-12-28 2015-09-09 大塚制药株式会社 包含光学活性托伐普坦的可注射储库制剂及制造该制剂的方法
CN110891939A (zh) * 2017-06-30 2020-03-17 大塚制药株式会社 苯并氮杂卓衍生物
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
CN112851583A (zh) * 2021-01-19 2021-05-28 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
WO2022156449A1 (zh) * 2021-01-19 2022-07-28 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途

Also Published As

Publication number Publication date
US20110071084A1 (en) 2011-03-24
PT2374797E (pt) 2014-05-02
US9073868B2 (en) 2015-07-07
EP2374798A1 (en) 2011-10-12
PT2374798E (pt) 2013-11-05
AR067176A1 (es) 2009-09-30
HK1163077A1 (en) 2012-09-07
US8785386B2 (en) 2014-07-22
JP5653043B2 (ja) 2015-01-14
TW200911271A (en) 2009-03-16
JP2014205703A (ja) 2014-10-30
PL2374798T3 (pl) 2014-01-31
AU2008269918B2 (en) 2012-12-06
HRP20120310T1 (hr) 2012-06-30
CA2690335A1 (en) 2008-12-31
DK2170831T3 (da) 2012-05-21
RU2010102229A (ru) 2011-08-10
IL202561A0 (en) 2010-06-30
CY1115226T1 (el) 2017-01-04
MY152805A (en) 2014-11-28
JP2010531293A (ja) 2010-09-24
JP5689195B2 (ja) 2015-03-25
JP5893085B2 (ja) 2016-03-23
EP2374798B1 (en) 2013-09-04
NZ598064A (en) 2013-04-26
NZ581723A (en) 2012-03-30
KR20100040873A (ko) 2010-04-21
CY1114491T1 (el) 2016-10-05
PH12012501363A1 (en) 2014-04-28
PT2170831E (pt) 2012-04-13
HK1141994A1 (en) 2010-11-26
EP2170831A1 (en) 2010-04-07
SG182231A1 (en) 2012-07-30
ATE545633T1 (de) 2012-03-15
US8669229B2 (en) 2014-03-11
ES2460018T3 (es) 2014-05-13
HK1163660A1 (en) 2012-09-14
NZ598067A (en) 2012-12-21
EP2374797A1 (en) 2011-10-12
ES2431515T3 (es) 2013-11-26
MY148312A (en) 2013-03-29
HRP20140501T1 (hr) 2014-07-04
PL2170831T3 (pl) 2012-08-31
DK2374798T3 (da) 2013-10-07
WO2009001968A1 (en) 2008-12-31
MY150941A (en) 2014-03-14
SI2374797T1 (sl) 2014-05-30
EP2374797B1 (en) 2014-03-26
CN103342680A (zh) 2013-10-09
UA98966C2 (ru) 2012-07-10
BRPI0813768A2 (pt) 2014-12-30
PL2374797T3 (pl) 2014-08-29
AU2008269918A1 (en) 2008-12-31
DK2374797T3 (da) 2014-05-12
RU2471784C2 (ru) 2013-01-10
SI2170831T1 (sl) 2012-04-30
JP2014208680A (ja) 2014-11-06
TWI459947B (zh) 2014-11-11
EP2170831B1 (en) 2012-02-15
KR101487201B1 (ko) 2015-01-28
HRP20131095T1 (hr) 2014-01-03
CY1113519T1 (el) 2016-06-22
PH12012501362A1 (en) 2014-04-28
SI2374798T1 (sl) 2013-10-30
CO6160295A2 (es) 2010-05-20
SG182230A1 (en) 2012-07-30
ES2380085T3 (es) 2012-05-08
US20140024619A1 (en) 2014-01-23
CN103342679A (zh) 2013-10-09
US20140024640A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
CN101687805A (zh) 可用作血管加压素拮抗剂的苯并氮杂衍生物
EP0354583B1 (en) DC-88A derivatives
DK160983B (da) Analogifremgangsmaade til fremstilling af tricycliske aminosyrer eller deres fysiologisk acceptable salte samt derved anvendelige mellemprodukter
JP5656399B2 (ja) 医薬及び医薬製剤
KR100382998B1 (ko) 6-메톡시-1h-벤조트리아졸-5-카르복사미드유도체,그제조방법및그것을함유하는의약조성물
JPS597168A (ja) カルボスチリル誘導体
HK1163660B (en) Benzazepine derivatives useful as vasopressin antagonists
HK1141994B (en) Benzazepine derivatives useful as vasopressin antagonists
HK1163077B (en) Benzazepine derivatives useful as vasopressin antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20100331